Key terms
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CDTX news
Apr 22
5:13pm ET
Cidara Therapeutics reports Q4 EPS (4c), consensus (10c)
Apr 22
5:08pm ET
Cidara Therapeutics discloses Nasdaq listing deficiency notice
Apr 22
8:55am ET
Cidara Therapeutics announces 1-for-20 reverse stock split
Apr 08
10:45am ET
Buy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program Developments
Feb 12
8:06am ET
Cidara Therapeutics receives $11.14M milestone payment from Mundipharma
Feb 10
4:05am ET
Cidara Therapeutics Granted Nasdaq Listing Extension
Jan 29
4:48pm ET
Cidara spikes 20% after MHRA approval of Rezzayo for invasive candidiasis
Jan 29
4:40pm ET
Cidara gets $2.8M milestone payment from Mundipharma for MHRA’s Rezzayo approval
Jan 29
4:37pm ET
MHRA approves Cidara Therapeutics’ Rezzayo for invasive candidiasis in adults
No recent press releases are available for CDTX
CDTX Financials
Key terms
Ad Feedback
CDTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CDTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range